Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
Discovery Medicine|May 28, 2016
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cellsBryan Oronsky, Jan Scicinski, Tony Reid, et al.
Oxford Medical Case Reports|December 18, 2019
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patientsMichael Bouvet, Tony R Reid, Chris Larson, et al.
Molecular Pharmaceutics|May 1, 2019
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in MiceBryan Oronsky, Eilleen S Y Ao-Ieong, Ozlem Yalcin, et al.
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Nucleocapsid as a next-generation COVID-19 vaccine candidateBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Cancers|October 14, 2022
Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns HotBryan Oronsky, Brian Gastman, Anthony P Conley, et al.
Journal for Immunotherapy of Cancer|June 17, 2024
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believingAnthony Conley, Christopher Larson, Bryan Oronsky, et al.
Discovery Medicine|May 28, 2016
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cellsBryan Oronsky, Jan Scicinski, Tony Reid, et al.
Oxford Medical Case Reports|December 18, 2019
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patientsMichael Bouvet, Tony R Reid, Chris Larson, et al.
Molecular Pharmaceutics|May 1, 2019
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in MiceBryan Oronsky, Eilleen S Y Ao-Ieong, Ozlem Yalcin, et al.
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Nucleocapsid as a next-generation COVID-19 vaccine candidateBryan Oronsky, Christopher Larson, Scott Caroen, et al.
Oncoimmunology|January 18, 2021
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky, Corey A Carter, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Oncotarget|May 29, 2018
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cellsBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Pageof 12